| Overview |
| bs-0216R-Cy7 |
| Fas Ligand Polyclonal Antibody, Cy7 Conjugated |
| WB, FCM, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat, Pig |
| Cow |
| Specifications |
| Cy7 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human Fas Ligand |
| 196-281/281 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 356 |
| P48023 |
| Nucleus, Secreted, Cell membrane, Extracellular matrix |
| APTL; FASL; CD178; CD95L; ALPS1B; CD95-L; TNFSF6; APT1LG1; Tumor necrosis factor ligand superfamily member 6; Apoptosis antigen ligand; CD95 ligand; Fas antigen ligand; Fas ligand; FASLG |
| Cytokine that binds to TNFRSF6/FAS, a receptor that transduces the apoptotic signal into cells. May be involved in cytotoxic T-cell mediated apoptosis and in T-cell development. TNFRSF6/FAS-mediated apoptosis may have a role in the induction of peripheral tolerance, in the antigen-stimulated suicide of mature T-cells, or both. Binding to the decoy receptor TNFRSF6B/DcR3 modulates its effects. The FasL intracellular domain (FasL ICD) cytoplasmic form induces gene transcription inhibition. |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz